The current and projected economic burden of Parkinson's disease in the United States - PubMed (original) (raw)
doi: 10.1002/mds.25292. Epub 2013 Feb 21.
Affiliations
- PMID: 23436720
- DOI: 10.1002/mds.25292
The current and projected economic burden of Parkinson's disease in the United States
Stacey L Kowal et al. Mov Disord. 2013 Mar.
Abstract
Parkinson's disease (PD), following Alzheimer's disease, is the second-most common neurodegenerative disorder in the United States. A lack of treatment options for changing the trajectory of disease progression, in combination with an increasing elderly population, portends a rising economic burden on patients and payers. This study combined information from nationally representative surveys to create a burden of PD model. The model estimates disease prevalence, excess healthcare use and medical costs, and nonmedical costs for each demographic group defined by age and sex. Estimated prevalence rates and costs were applied to the U.S. Census Bureau's 2010 to 2050 population data to estimate current and projected burden based on changing demographics. We estimate that approximately 630,000 people in the United States had diagnosed PD in 2010, with diagnosed prevalence likely to double by 2040. The national economic burden of PD exceeds 14.4billionin2010(approximately14.4 billion in 2010 (approximately 14.4billionin2010(approximately22,800 per patient). The population with PD incurred medical expenses of approximately 14billionin2010,14 billion in 2010, 14billionin2010,8.1 billion higher ($12,800 per capita) than expected for a similar population without PD. Indirect costs (e.g., reduced employment) are conservatively estimated at 6.3billion(orcloseto6.3 billion (or close to 6.3billion(orcloseto10,000 per person with PD). The burden of chronic conditions such as PD is projected to grow substantially over the next few decades as the size of the elderly population grows. Such projections give impetus to the need for innovative new treatments to prevent, delay onset, or alleviate symptoms of PD and other similar diseases.
Copyright © 2012 Movement Disorders Society.
Similar articles
- Burden of illness in Parkinson's disease.
Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Huse DM, et al. Mov Disord. 2005 Nov;20(11):1449-54. doi: 10.1002/mds.20609. Mov Disord. 2005. PMID: 16007641 - Economic costs of diabetes in the U.S. In 2007.
American Diabetes Association. American Diabetes Association. Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Diabetes Care. 2008. PMID: 18308683 Review. - Drug and treatment costs in Parkinson's disease patients in Sweden.
Lökk J, Borg S, Svensson J, Persson U, Ljunggren G. Lökk J, et al. Acta Neurol Scand. 2012 Feb;125(2):142-7. doi: 10.1111/j.1600-0404.2011.01517.x. Epub 2011 Apr 6. Acta Neurol Scand. 2012. PMID: 21470194 - Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries.
Noyes K, Liu H, Li Y, Holloway R, Dick AW. Noyes K, et al. Mov Disord. 2006 Mar;21(3):362-72. doi: 10.1002/mds.20727. Mov Disord. 2006. PMID: 16211621 - Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment.
Chen JJ. Chen JJ. Am J Manag Care. 2010 Mar;16 Suppl Implications:S87-93. Am J Manag Care. 2010. PMID: 20297871 Review.
Cited by
- Upregulation of Glutaredoxin-1 Activates Microglia and Promotes Neurodegeneration: Implications for Parkinson's Disease.
Gorelenkova Miller O, Behring JB, Siedlak SL, Jiang S, Matsui R, Bachschmid MM, Zhu X, Mieyal JJ. Gorelenkova Miller O, et al. Antioxid Redox Signal. 2016 Dec 20;25(18):967-982. doi: 10.1089/ars.2015.6598. Epub 2016 Jun 27. Antioxid Redox Signal. 2016. PMID: 27224303 Free PMC article. - Association between use of ß2-adrenergic receptor agonists and incidence of Parkinson's disease: Retrospective cohort analysis.
Nadeem H, Zhou B, Goldman D, Romley J. Nadeem H, et al. PLoS One. 2022 Nov 28;17(11):e0276368. doi: 10.1371/journal.pone.0276368. eCollection 2022. PLoS One. 2022. PMID: 36441791 Free PMC article. - Identifying Protective Drugs for Parkinson's Disease in Health-Care Databases Using Machine Learning.
Courtois É, Nguyen TTH, Fournier A, Carcaillon-Bentata L, Moutengou É, Escolano S, Tubert-Bitter P, Elbaz A, Thiébaut ACM, Ahmed I. Courtois É, et al. Mov Disord. 2022 Dec;37(12):2376-2385. doi: 10.1002/mds.29205. Epub 2022 Aug 29. Mov Disord. 2022. PMID: 36054665 Free PMC article. - Proof of Concept in Artificial-Intelligence-Based Wearable Gait Monitoring for Parkinson's Disease Management Optimization.
Ileșan RR, Cordoș CG, Mihăilă LI, Fleșar R, Popescu AS, Perju-Dumbravă L, Faragó P. Ileșan RR, et al. Biosensors (Basel). 2022 Mar 23;12(4):189. doi: 10.3390/bios12040189. Biosensors (Basel). 2022. PMID: 35448249 Free PMC article. - Regional transcriptional architecture of Parkinson's disease pathogenesis and network spread.
Freeze B, Pandya S, Zeighami Y, Raj A. Freeze B, et al. Brain. 2019 Oct 1;142(10):3072-3085. doi: 10.1093/brain/awz223. Brain. 2019. PMID: 31359041 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical